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Abstract 
The main focus here is on the improvement of formulations utilising non-conventional bio-based 
excipients to improve tablet release rates. Two different formulations were considered. The first 
formulation contains Alcell lignin, lactose monohydrate and microcrystalline cellulose as excipients 
and acetylsalicylic acid (aspirin) as active pharmaceutical ingredient (API). The second formulation 
contains lactose monohydrate and microcrystalline cellulose as excipients and aspirin as API. The 
prepared formulations were roller compacted followed by milling, sieving, and tableting. The 
tablets were then characterised in terms of dissolution rate in order to compare the release rates. 
Results indicated that tablets containing Alcell lignin have quicker release, faster disintegration 
times and higher tablet hardness for all samples with differing process parameters. Higher API 
dissolution has been attributed to the amorphous structure of lignin and its interaction with aspirin, 
which increases dissolution of the API. 
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Three different methods are considered for tablet manufacturing in the pharmaceutical industry, i.e. 
direct compaction, dry, and wet granulation. Recently, there has been focus on direct compaction 
due to cost and time effectiveness as less number of processing steps are involved. Moreover, the 
tablets produced by direct compaction have faster dissolution rates [1]. However, in order to 
improve powder flowability and bulk density, especially for poor flowing materials, granulation has 
proved useful. Dry granulation is continuous and is the preferred method for moisture and heat 
sensitive materials as no binder is used [2-6]. 
Today, one of the major challenges facing the pharmaceutical industry is to enhance the 
bioavailability which play a crucial role in drug development [7]. Tablet release rate has a 
significant effect on tablet bioavailability [8] in which higher release rates result in higher 
bioavailability and lower side effects. Currently, the most common method for enhancing the 
bioavailability of drugs is preparation of amorphous solid dispersion. In an amorphous solid 
dispersion (ASD), the API is transformed to amorphous phase from crystalline by various 
techniques, and then API is dispersed in a polymeric carrier, which enhances the dissolution of API 
molecules. 
Excipients are inert substances used in drug production to assist manufacturing and control the 
dosage, quality, stability, bioavailability, toxicity and efficacy [9-11]. For example, sugar 
compounds such as lactose and cellulose derivatives such as MCC are the most commonly used 
excipients in tablet manufacturing [10, 12, 13]. In this study, in order to investigate the effect of 
excipient on tablet release rate, disintegration and dissolution tests have been extensively studied 
[14-19]. Several researchers have illustrated that the influence of excipients on release of oral 
dosage drugs is significant [20]. The type of excipient, its physical and chemical properties, and 
interaction with API can effect processability and stability of tablets as well as overcome the drug 

















pharmaceutical production due to its considerable effect on disintegration, dissolution and drug 
release rate [7, 20, 22-24]. 
Various researchers have focused on improved tablet release rate and drug absorption, etc. by 
developing novel excipients. Due to some issues in relation to side effects and release rates of solid 
dosage forms [25], use of materials with desired functionality as excipient in tablets are increasing. 
In tablet manufacturing, amorphous materials are showing great promise as excipients as they 
exhibit higher dissolution compared to crystalline equivalents due to disordered structure and higher 
free energy [25-29]. On the other hand, the thermodynamic instability of amorphous excipients used 
in tablets, might result in relaxation and crystal growth of crystalline API molecules over time 
which is not favourable for bioavailability [30]. 
Recently, biological macromolecules have attracted attention for use as excipient in tablet 
production to enhance drug dissolution and bioavailability. A number of studies have been carried 
out on lignin to improve chemical modification [31-33], and to develop new pharmaceutical 
formulations with increased functionality [34, 35] because of lignin structure which contains 
phenolic and aliphatic hydroxyl groups [35]. Lignin has a high potential to be used in tablet 
manufacturing either with chemical modification or without chemical modification [32]. 
Furthermore, some researchers have investigated the ability of lignin’s nanoparticles (NPs) in drug 
delivery due to its non-toxicity, biodegradability and stability. Lignin has also been used to 
transport hydrophobic drugs [36]. Lignin is an amorphous polymer and non-amphiphilic in nature, 
and displays high chemical stability due to 3D network structure [37]. As lignin is rich in phenolic 
and aliphatic hydroxyl groups [38], it interacts with most API molecules through π-π stacking and 
hydrogen bonding, and this makes lignin potentially useful as a drug carrier to enhance 
bioavailability [16, 17, 21, 26, 28, 34, 37, 39-43]. 
Aspirin, which is known as a delayed-release drug is utilised as a model API in this work [44]. In 

















bioavailability. Moreover, another challenge associated with aspirin is that it hydrolyses to salicylic 
acid upon exposure to aqueous solutions, which should be taken into account during the dissolution 
tests [8, 15, 41, 45-47]. Wang et al. have investigated aspirin hydrolysis during dissolution tests, 
and found out that the hydrolysis of aspirin occurs during dissolution [47]. Sumirtapura et al. 
studied the dissolution of different types of acetylsalicylic acid products, and distinguished time 
lags for differing aspirin tablets [46]. Peltonen et al. utilised three different tablets containing aspirin 
for dissolution tests. The first type of tablets contained aspirin and MCC; the second ones consisted 
of aspirin and lactose, while the third ones included aspirin, lactose and MCC. They investigated the 
effect of pH on aspirin release rate and found higher release at higher pH. Moreover, they reported 
that adding lactose to aspirin in the formulation leads to increased release rate. On the other hand, 
adding MCC results in decreased release rate [15]. 
In comparison with other literature, the authors have tried to analyse the dissolution of different 
formulations containing aspirin as API and various excipients. Lignin was used as a new excipient 
to evaluate its performance in tablet manufacturing in order to improve drug release rates. Indeed, 
the purpose of this study is to investigate the effect of Alcell lignin on tablet properties including 
hardness, disintegration time and drug release rate. The main aim is to explore the possibility of 
using lignin as natural material to enhance bioavailability of poorly water-soluble drugs. Two 
different formulations are utilised, one formulation containing Alcell lignin and another one without 
lignin. First, two different blends are roller compacted to produce ribbons. Then, the produced 
ribbons are milled to make granules. Afterwards, these granules are used to produce tablets. 
Different tablet characterisation tests including; disintegration, hardness and dissolution tests are 
carried out to understand the effect of lignin as natural polymer on drug release rate. 
  
2. Experimental procedure 

















In order to prepare the formulations, acetylsalicylic acid (Alfa Aesar, 99% C9H8O4) was utilised as 
a model API. Different excipients were utilised including microcrystalline cellulose (MCC 
SANAQ
®
 102 L USP/NF/EP), lactose monohydrate (Lennox USP, NF, BP, Ph, pure pharma grade) 
and Alcell lignin (Tecnaro (Ilsfeld, Germany)). More details on the lignin used in this study can be 
found elsewhere [33, 48]. To prepare the mixtures, 1% w/w magnesium stearate (Sigma-Aldrich, 
Ph. Eur., BP, ≥90% stearic and palmitic acid basis), as lubricant and croscarmellose sodium (CCS) 
(IMCD NF, PH.Eur.,JP) as disintegrant were used in the formulations. Table 1 illustrates the two 
different formulations considered; in the first one; 5 wt. % of aspirin was mixed with 20 wt. % of 
lactose, 20 wt. % of lignin, 3 wt. % of CCS and 1 wt. % MgSt, and the rest is MCC 102. The 
second formulation was prepared with 5 wt. % of aspirin, 20 wt. % of lactose, 3 wt. % of CCS, 1 
wt. % MgSt, and the rest is MCC 102. All components were mixed using a Morphy Richards Stand 
Mixer. Ortho-phosphoric acid (analytical reagent grade, Fisher Scientific UK) and acetonitrile, 
HPLC grade, 99.7+% min Liquid (Alfa Aesar) were mixed to prepare mobile phase for HPLC 
analysis. 





2.2. Equipment and instruments 
2.2.1 Dry granulation by roll compaction and milling process 
To prepare the tablets, the dry granulation method was used for the entirety of this work in a series 
of ribbon production, milling, and tabletting. The ribbons were produced using a roller compactor 
Material A B 
Acetylsalicylic acid (% wt.) 5 5 
Alcell lignin (% wt.) 20 0 
Lactose (% wt.) 20 20 
MCC 102 (% wt.) 51 71 
Croscarmellose sodium (% wt.) 3 3 

















(Freund TF-MINI) integrated with a vertical screw feeder for feeding the formulations. The rollers 
dimensions are 100 mm in diameter and 25 mm in width. The considered process parameters 
included screw speed (SS) and roll pressure (RP), while roll speed was kept constant at 4 rpm. The 
screw speed was changed between 10-14 rpm, and roll pressure was changed between 30-50 bars in 
the ribbon production experiments. The density of produced ribbons were measured using GeoPyc 
density analyser (Micrometrics Instrument Corp., Norcross – USA). The produced ribbons were 
then milled using a conical mill (Laboratory Comil 193 AS) with mesh size of 813 µm, and 
impeller speed of 3000 rpm. The particle size distribution (PSD) of fine powder and granules were 
measured using Microtrac S3500 particle size analyser. 
2.2.2 Tablet preparation and characterisation 
A benchtop single punch tablet press (Gamlen Tableting GTD-1 D series) was used to produce the 
tablets with different formulations. 100 mg of two different formulations of produced granules were 
pressed to make tablets in a 6 mm (diameter) die. The tablet compression was carried out at 180 
mm/min speed under fixed load of 400 kg. Croscarmellose sodium was used as super disintegrant in 
tablet preparation experiments [23]. 
Hardness of the produced tablets was measured using a tablet hardness tester (Pharma Test 
PTB311E). To measure the disintegration time, Pharma Test PTZ-DIST- Disintegration Test 
Instrument (Hainburg, Germany) was used. The apparatus chamber was filled with 900 mL of 
deionized water and the apparatus paddle was adjusted at 100 rpm. Three samples were tested in 
deionized water at 37 ̊ C for each process parameters and for two different formulations. All the 
disintegration tests were conducted until the tablets completely disintegrate. The dissolution of 
produced tablets was performed using a Pharma Test PTWS 120D 6-Station Tablet Dissolution 
Testing Instrument (Hainburg, Germany). 
The concentration of the API in each sample was measured using High Performance Liquid 

















Waldbronn, Germany) 1260 Infinity II HPLC system. The HPLC system consisted of a quaternary 
pump G1311B, a diode array detector G1315D set at wavelengths of 200 nm for acetylsalicylic acid 
and salicylic acid, auto-sampler G1329 B and a thermostated column compartment G1316A set at 
25 
°
C. The system operated under isocratic flow at 0.75 mL/min using mobile phases consisting of 
A) 0.1 % Ortho-phosphoric acid; B) acetonitrile; A/B =50/50, v/v. The injection volume was 10 
mL. The total run time was 10 minutes, and the type of column used was Kromasil 5C18 (250×4.6 
mm). 
2.3. Dissolution test procedure 
The dissolution chamber was filled with 500 mL of prepared medium 0.1 N HCl (ACS, ISO, Reag. 
Ph Eur, Hydrochloric acid fuming 37% wt.) at pH=1.2. The medium temperature was kept constant 
at 37 ± 0.5 ̊ C and the stirrer was adjusted to a speed of 75 rpm [45]. When the temperature reached 
37 ̊ C, one tablet was placed in each dissolution vessel to run the dissolution test for 120 minutes. 
Three mL of the dissolution medium were withdrawn at 5, 10, 20, 30, 40, 50, 60 and 120 minutes, 
then medium was replaced with the same amount, immediately. Then, the samples were filtered 
using Captiva Econofilters (PTFE membrane, 13 mm diameter, 0.2-µm pore size) syringes to 
prepare for the analysis by HPLC at 200 nm wavelength, immediately, due to hydrolysis of 
acetylsalicylic acid. 
 In order to prepare the buffer solution (pH = 1.2) for the dissolution tests, 2 g sodium chloride was 
dissolved in 200 mL deionized water. Then, it was diluted with deionized water in a 1000 mL 
volumetric flask and 7 mL HCl was added. In order to prepare the calibration solutions for HPLC 
analysis, 5 mg of acetylsalicylic acid and 5 mg salicylic acid were dissolved in 20 mL of buffer 
solution, separately. Then, they were mixed to prepare the calibration solution. Afterwards, the 
prepared solutions were diluted with buffer solution 6 times. The standard curves of drug 
concentration vs peak area were drawn for different formulations giving R
2
= 0.99. 

















3.1. Dissolution profiles for two different formulations 
Two different formulations were evaluated to find the effect of Alcell lignin on the aspirin tablet 
release rate. One formulation contains Alcell lignin, MCC 102 and lactose as excipients and the 
other one contains lactose and MCC 102 as excipients. Both formulations contain aspirin as API. 
Fig. 1 illustrates the graphs of drug release rate for tablets prepared at various process parameters. 
As seen, different levels of screw speed and roll pressure were considered in this study. 
Interestingly, the results show that the tablets containing Alcell lignin have higher release rate than 
the tablets without lignin for all prepared samples. In addition, the equilibrium dissolution for the 
tablets containing lignin is greater which is attributed to the enhancement of solubility of ASA with 
addition of lignin. It is also seen that faster release kinetics is obtained for the tablets containing 
lignin such that the majority of the API are dissolved in the first 10 minutes of the dissolution test. 
Moreover, the tablets prepared with lignin indicated less variability in the dissolution 
measurements. The data is provided in the Supplementary file for both formulations. 
In other words, tablets containing lignin with very high release rate acts as a disintegrating agent in 
the dissolution chamber, facilitate the dissolution kinetics, and accelerate to equilibrium release. 
Moreover, due to amorphous nature of lignin, it may be concluded that lignin enhances the 
solubility of API due to its disordered structure and higher Gibbs free energy of the amorphous 
phase in the dissolution media. The cross-linked structure of lignin is likely to have an effect on 
dissolution and disintegration as well. Peltonen et al. [15] studied the effect of pH on the release 
rate of aspirin tablets with different formulations (B (aspirin & lactose), A (aspirin, lactose &MCC) 
and C (aspirin &MCC)). They illustrated in pH 1.2 the release rate of aspirin with the different 
formulations are low and it does not show 100% release rate after  more than 200 minutes. 
Maximum release rates of the formulation B was around 90% after 200 minutes. For formulation A, 


















The roll compaction process parameters affect the release rate of aspirin also in which the effect of 
roll pressure is more significant compared to screw speed. For the tablets without lignin, increasing 
roll pressure (at constant screw speed of 14 rpm) results in reduction of API dissolution, which 
could be attributed to the particle size of granules, which produce the tablets. In the roll compaction 
process, increasing the roll pressure results in enhancement of granule size. However, the effect of 
process parameters on the API dissolution is not significant, because the dissolution depends mainly 
on the chemical structure of API and interaction with the dissolution medium. In fact, the 





































































































































Figure 1: Dissolution release rate of acetylsalicylic acid for different lignin and non-lignin tablets at 
different process parameters. 
 
3.2. Effect of process parameters on tablet disintegration time 
The effect of roll pressure and screw speed as the main process parameters of dry granulation on the 
tablet disintegration time for the two formulations is shown in Fig. 2. In terms of the effect of roll 
pressure as process parameter on disintegration time of tablets, the results illustrate that increasing 
the roll pressure while keeping the screw speed constant, results in decreasing the disintegration 
time for both formulations. Increasing the roll pressure results in higher densify of ribbons during 
































































energy is required to break up the ribbons during the milling step. The tablets made with larger 
granules will be more porous, and subsequently leads to faster disintegration time. It is also 
observed from Fig. 2 that the tablets containing lignin have faster disintegration time than non-
lignin tablets due to the amorphous and inherent structure of lignin, which has higher affinity 
towards the solution media compared to MCC and lactose. 
Moreover, the particle size of raw materials used as excipients are shown in Fig. 3. As observed, 
lignin has smaller particle size compared to MCC 102, and introducing lignin as an excipient results 
in better compaction behaviour. In fact, smaller particles provide better particle-particle contact 
during the roll compaction and denser ribbons are produced, which in turn results in larger granules 
in the milling stage [49]. Furthermore, the size distributions of the used granules for tableting are 
shown in the Supplementary file. It is seen that the formulation containing lignin has slightly larger 
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Figure 3: Particle size distribution of materials; MCC 102, lactose and lignin. 
3.3. Effect of process parameters on tablet hardness 
Fig. 4 illustrates the hardness of the tablets prepared using the two formulations as a function of 
process parameters. The results reveal that the lignin tablets have higher hardness than non-lignin 
tablets for all samples. Also, it can be seen that increasing the roll pressure leads to reduction of 
tablet hardness due to larger granules being obtained at higher roll pressure which in turn leads to 
weak physical bonds between particles. The results also indicate that by increasing screw speed, the 
tablet hardness decreases; however, the change is not considerable. In addition, the standard range 
of tablet hardness is between 39-79 N, therefore the lignin tablets are within the standard range of 
hardness. The reason why tablets containing lignin display higher hardness can be attributed to the 
interaction between lignin and other constituents of the formulation where lignin acts as a binder 




































Figure 4: Hardness of tablets prepared with and without lignin as function of process parameters. 
 
4. Conclusions 
The main aim of this study was to investigate the effect of lignin-based excipients on release of oral 
dosage aspirin tablets. Lignin was selected as an excipient to evaluate its influence on release rate 
and tablet properties at varying processing conditions due its chemical structure. Results illustrated 
that lignin tablets compared to non-lignin tablets have higher hardness, faster disintegration time, 
and higher release rate. Indeed, the critical quality attributes of the tablets were improved by 
introducing the lignin. Higher release rate of tablets with lignin formulation are due to amorphous 
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bioavailability, the key factor in oral dosage development. On the other hand, higher roll pressure 
leads to more densified ribbons associated with lignin blends and consequently, larger granules are 
produced. These larger granules result in porous tablets, which leads to faster disintegration times as 
solute diffuses faster into the tablets. Also, the greater hardness for the tablets containing lignin are 
attributed to better affinity between lignin and MCC which leads to lignin acting as a tablet binder. 
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